These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 33723386)

  • 1. Effects of cancer screening restart strategies after COVID-19 disruption.
    Kregting LM; Kaljouw S; de Jonge L; Jansen EEL; Peterse EFP; Heijnsdijk EAM; van Ravesteyn NT; Lansdorp-Vogelaar I; de Kok IMCM
    Br J Cancer; 2021 Apr; 124(9):1516-1523. PubMed ID: 33723386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of the COVID-19 pandemic on faecal immunochemical test-based colorectal cancer screening programmes in Australia, Canada, and the Netherlands: a comparative modelling study.
    de Jonge L; Worthington J; van Wifferen F; Iragorri N; Peterse EFP; Lew JB; Greuter MJE; Smith HA; Feletto E; Yong JHE; Canfell K; Coupé VMH; Lansdorp-Vogelaar I;
    Lancet Gastroenterol Hepatol; 2021 Apr; 6(4):304-314. PubMed ID: 33548185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Oncological organized screening programmes in the COVID-19 era: an Italian survey on accrued delays, reboot velocity, and diagnostic delay estimates].
    Mantellini P; Battisti F; Armaroli P; Giubilato P; Ventura L; Zorzi M; Battagello J; Sassoli de Bianchi P; Senore C; Zappa M
    Epidemiol Prev; 2020; 44(5-6 Suppl 2):344-352. PubMed ID: 33412828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Cancer Screening Deficit in the United States With the COVID-19 Pandemic.
    Chen RC; Haynes K; Du S; Barron J; Katz AJ
    JAMA Oncol; 2021 Jun; 7(6):878-884. PubMed ID: 33914015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prioritisation of colonoscopy services in colorectal cancer screening programmes to minimise impact of COVID-19 pandemic on predicted cancer burden: A comparative modelling study.
    van Wifferen F; de Jonge L; Worthington J; Greuter MJE; Lew JB; Nadeau C; van den Puttelaar R; Feletto E; Yong JHE; Lansdorp-Vogelaar I; Canfell K; Coupé VMH;
    J Med Screen; 2022 Jun; 29(2):72-83. PubMed ID: 35100894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling Strategies to Optimize Cancer Screening in USPSTF Guideline-Noncompliant Women.
    Taksler GB; Peterse EFP; Willems I; Ten Haaf K; Jansen EEL; de Kok IMCM; van Ravesteyn NT; de Koning HJ; Lansdorp-Vogelaar I
    JAMA Oncol; 2021 Jun; 7(6):885-894. PubMed ID: 33914025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recovering cancer screening in the pandemic: strategies and their impacts.
    Morrison DS
    Br J Cancer; 2021 Apr; 124(9):1465-1466. PubMed ID: 33723387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A modelled evaluation of the impact of COVID-19 on breast, bowel, and cervical cancer screening programmes in Australia.
    Nickson C; Smith MA; Feletto E; Velentzis LS; Broun K; Deij S; Grogan P; Hall M; He E; St John DJ; Lew JB; Procopio P; Simms KT; Worthington J; Mann GB; Canfell K
    Elife; 2023 Apr; 12():. PubMed ID: 37022767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Le disuguaglianze di accesso ai programmi di screening dei tumori della mammella, del colon retto e della cervice uterina sono aumentate durante il periodo pandemico. Risultati di un health equity audit condotto dall'Agenzia di Tutela della Salute d.
    Girardi D; Vecchio R; Tanious M; Cacitti S; Ancarani C; Dalle Carbonare S; Perotti P; Bonafede C; Cavallo R; Gentile L; Parrini A; Lucente EM; Carlesso A; Cadum E; Cecconami L; Odone A; Deandrea S
    Epidemiol Prev; 2024; 48(2):130-139. PubMed ID: 38770730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of COVID-19 on screening for colorectal, gastric, breast, and cervical cancer in Korea.
    Park H; Seo SH; Park JH; Yoo SH; Keam B; Shin A
    Epidemiol Health; 2022; 44():e2022053. PubMed ID: 35760396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of COVID-19 in Cervical and Breast Cancer Screening and Systemic Treatment in São Paulo, Brazil: An Interrupted Time Series Analysis.
    Duarte MBO; Argenton JLP; Carvalheira JBC
    JCO Glob Oncol; 2022 Jun; 8():e2100371. PubMed ID: 35696624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A population-based survey of self-reported delays in breast, cervical, colorectal and lung cancer screening.
    Gunn CM; Berrian K; Weiss JE; Tosteson AAN; Hasson RM; Di Florio-Alexander R; Peacock JL; Rees JR
    Prev Med; 2023 Oct; 175():107649. PubMed ID: 37517458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of the temporary suspension of national cancer screening programmes due to the COVID-19 epidemic on the diagnosis of breast and colorectal cancer in the Netherlands.
    Dinmohamed AG; Cellamare M; Visser O; de Munck L; Elferink MAG; Westenend PJ; Wesseling J; Broeders MJM; Kuipers EJ; Merkx MAW; Nagtegaal ID; Siesling S
    J Hematol Oncol; 2020 Nov; 13(1):147. PubMed ID: 33148289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A national quality improvement study identifying and addressing cancer screening deficits due to the COVID-19 pandemic.
    Joung RH; Nelson H; Mullett TW; Kurtzman SH; Shafir S; Harris JB; Yao KA; Brajcich BC; Bilimoria KY; Cance WG
    Cancer; 2022 Jun; 128(11):2119-2125. PubMed ID: 35307815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of the randomized control screening trials on oral, cervix and breast cancer from India and way forward in COVID-19 pandemic situation.
    Budukh AM; Dikshit R; Chaturvedi P
    Int J Cancer; 2021 Oct; 149(8):1619-1620. PubMed ID: 34152021
    [No Abstract]   [Full Text] [Related]  

  • 16. Variation in Screening Abnormality Rates and Follow-Up of Breast, Cervical and Colorectal Cancer Screening within the PROSPR Consortium.
    Tosteson AN; Beaber EF; Tiro J; Kim J; McCarthy AM; Quinn VP; Doria-Rose VP; Wheeler CM; Barlow WE; Bronson M; Garcia M; Corley DA; Haas JS; Halm EA; Kamineni A; Rutter CM; Tosteson TD; Trentham-Dietz A; Weaver DL;
    J Gen Intern Med; 2016 Apr; 31(4):372-9. PubMed ID: 26658934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19 and cancer screening in Scotland: A national and coordinated approach to minimising harm.
    Campbell C; Sommerfield T; Clark GRC; Porteous L; Milne AM; Millar R; Syme T; Thomson CS
    Prev Med; 2021 Oct; 151():106606. PubMed ID: 34217418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating Screening Participation, Follow-up, and Outcomes for Breast, Cervical, and Colorectal Cancer in the PROSPR Consortium.
    Barlow WE; Beaber EF; Geller BM; Kamineni A; Zheng Y; Haas JS; Chao CR; Rutter CM; Zauber AG; Sprague BL; Halm EA; Weaver DL; Chubak J; Doria-Rose VP; Kobrin S; Onega T; Quinn VP; Schapira MM; Tosteson ANA; Corley DA; Skinner CS; Schnall MD; Armstrong K; Wheeler CM; Silverberg MJ; Balasubramanian BA; Doubeni CA; McLerran D; Tiro JA
    J Natl Cancer Inst; 2020 Mar; 112(3):238-246. PubMed ID: 31292633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Scelte gestionali per sostenere e migliorare i programmi di screening oncologico.
    Chiereghin A; Squillace L; Pizzi L; Sanna T; Bazzani C; Roti L; Mezzetti F
    Epidemiol Prev; 2024; 48(2):158-164. PubMed ID: 38770733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of the COVID-19 pandemic on oncology screenings: it is time to change course.
    Scioscia M; Noventa M; Palomba S; Laganà AS
    BJOG; 2021 Dec; 128(13):2213-2214. PubMed ID: 34402585
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.